-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Olema Pharmaceuticals, Lowers Price Target to $46

Benzinga·08/13/2026 15:28:20
Listen to the news
JP Morgan analyst Anupam Rama maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Overweight and lowers the price target from $52 to $46.